NEM brand eggshell membrane has been shown previously to reduce pro-inflammatory cytokines in vitro in mitogen-challenged, healthy human immune cells— and now this mechanism of action has been extended to in vivo studies as well. The results from these studies, recently published in Modern Research in Inflammation, showed substantial reductions of a variety of pro-inflammatory cytokines while, importantly, having little effect on the anti-inflammatory cytokines evaluated. The initial studies in healthy rats demonstrated large reductions (up to 88%) in cytokines that occur later in the inflammatory cascade (e.g. MCP-1, MIP-1β, RANTES, VEGF). Whereas a follow-up study in inflammatory-challenged rats demonstrated significant reductions (40-44%) in IL-1β, a key primary mediator of inflammation.
Kevin J. Ruff, Ph.D., MBA, CCRP, director of scientific & regulatory affairs for ESM Technologies stated, “We were pleased to find evidence that NEM helps to maintain a normal inflammatory response in healthy animals. And the novel nature of this finding formed the basis for a patent (U.S. 8,580,315) that was recently granted for this same indication.”
For more information: www.esmingredients.com